Introduction
============

Lateral epicondylitis (LE) is a common disease characterized by decreased grip and upper-extremity strength, along with pain on the outside of the elbow. It is pathology of the musculoskeletal system, secondary to recurrent microtrauma because of overuse of the upper extremity, causing pain and tenderness in the elbow area.[@b1-jpr-11-1459]--[@b3-jpr-11-1459] It is also known as "tennis elbow", and is observed in 5%--10% of tennis players.[@b4-jpr-11-1459] The annual incidence in the population is 1%--3%,[@b5-jpr-11-1459] with people aged 35--50 years and older being most commonly affected.[@b6-jpr-11-1459],[@b7-jpr-11-1459] Clinically, it is characterized by pain radiating from the lateral aspect of the elbow to the forearm and loss of function because of decrease in grip strength secondary to tenderness and pain at compression in the lateral epicondyle, and it is more frequently seen in the dominant hand.[@b5-jpr-11-1459],[@b8-jpr-11-1459]

Conservative approaches or surgical therapy can be used in the treatment of LE. The purpose of conservative treatment is to decrease pain, control inflammation, accelerate healing, and ensure that the patient performs daily life activities smoothly. While progressive strengthening is the most commonly used method among conservative treatment methods, other methods include watchful waiting, local injection, ultrasound, manipulation, manual therapy, Cyrax, lateral glide technique, extracorporeal shock-wave therapy (ESWT), laser, splinting, resting, hot--cold application, electrotherapy, massage, and oral or topical nonsteroidal anti-inflammatory drugs.[@b9-jpr-11-1459],[@b10-jpr-11-1459] Recently, ESWT has been used more commonly than other treatment methods, because it is noninvasive, well tolerated by patients, and has fewer side effects.[@b11-jpr-11-1459],[@b12-jpr-11-1459] However, the efficacy of ESWT in LE is controversial. Some studies have reported that ESWT is barely effective or as effective as placebo in LE.[@b13-jpr-11-1459],[@b14-jpr-11-1459] However, some other studies have reported that it is quite effective and could even be an alternative to surgery.[@b15-jpr-11-1459],[@b16-jpr-11-1459]

Splinting, another conservative treatment method, is one of the most commonly used methods in LE, because it is noninvasive, painless, and easy to apply. Although splints are usually prescribed in LE, their efficacy remains controversial.[@b17-jpr-11-1459] In the chronic period of LE, most commonly forearm-counterforce braces and wrist-extensor splints (WESs) are used as proprioceptive input.[@b8-jpr-11-1459] A WES inhibits contraction of extensor muscles and thus muscle expansion in the proximal third of the forearm, decreases the movement of tendinous structures, and thus decreases stress at the common extensor origin.[@b8-jpr-11-1459],[@b18-jpr-11-1459] Although clinical examination is easily accepted by patients because of painless and easy diagnosis, conservative treatment is either not completed or delayed by patients, since treatment options take a long time and restrict daily life activities. In this study, we planned to evaluate clinical and demographic characteristics, pain, and quality of life in patients with LE receiving ESWT and WES and compare the data of two groups.

Methods
=======

The was a planned prospective randomized controlled study, and conducted in accordance with the World Medical Association, Declaration of Helsinki, and the International Council for Harmonisation guidelines for good clinical practice. The study protocol was approved by the Dicle University Medical School ethics committee (DUTF-2013--79). In addition, participants were informed about the study. Written and verbal consent was received from all participants. In the scope of the study, a total of 67 patients (33 females and 34 males) who had been treated based on a diagnosis of unilateral LE between September 2015 and May 2017 were evaluated. The mean age was 38.84±6.77 years in the ESWT group and 37.94±6.45 years in the WES group, and the mean body mass index was 27.21±1.38 in the ESWT group and 26.340±2.29 in the WES group. [Figure 1](#f1-jpr-11-1459){ref-type="fig"} shows the schema for the patients' records.

The clinical diagnosis of LE was made with physical examination. In addition, standard anteroposterior and lateral elbow radiographs were obtained. Patients with pain in the lateral elbow, local tenderness to palpation on the lateral epicondyle, pain in the lateral elbow with resisted wrist extension, and patients with positive Mill's test[@b19-jpr-11-1459] results were included in the study. Patients with bilateral LE, carpal tunnel syndrome, cubital tunnel syndrome, previous elbow surgery, previous conservative and surgical treatment for LE, neurological deficits in the upper extremity, systemic disease, other diseases in the neck and shoulder region, lateral epicondylar tendon ruptures, tumors in the forearm and elbow, osteoporosis, and hemophilia were excluded from the study. All patients were instructed to avoid taking painkillers during the treatment and follow-up period. All patients were provided information on the procedures of the study.

Study groups
------------

Patients receiving ESWT were designated as group 1 (32 patients) and those receiving WES as group 2 (35 patients). In the ESWT group (group 1 -- 32 LE), four sessions of ESWT were delivered once per week. In each session, an ESWT device (DolorClast; EMS, Nyon, Switzerland) at 12 Hz, 2,000 pulses, and 1.8 bar pressure was used. Shock waves can be focal or radial. Focal shock waves have deeper tissue penetration (10 cm) and a higher power effect (0.08--0.28 mJ/mm^2^). Focal shock waves are not used for musculoskeletal disorders, because of their high energy and difficulty of application. Radial shock waves have lower penetration (3 cm), lower effect (0.02--0.06 mJ/mm^2^), and limited biological effect.[@b20-jpr-11-1459] Radial ESWT has been shown to be effective in more superficial musculoskeletal disorders, because of the limited amount of energy, simplicity of use, no need for sedation, and no need for monitoring with radiographic or echographic devices.[@b21-jpr-11-1459] Radial ESWT is commonly used in musculoskeletal diseases. The application was performed while the patient was in a sitting position with the shoulder at 45° abduction, elbow flexed, and forearm supported in a supine position. ESWT was applied to the most tender spot on the lateral epicondyle and surrounding area. No local anesthetic or analgesic medication was administered before or during application. In the WES group (group 2 -- 35 LE), a wrist splint (Manu Comfort; Ottobock, Duderstadt, Germany) holding the wrist at 30°--45° extension was applied for 4 weeks. The patients were randomized using a numbered-envelope method. Both groups were given wrist-and forearm-strengthening isokinetic exercises.

Measurement parameters
----------------------

Patients were evaluated for grip strength, pain at rest, pain while working, and quality of life. The same physiotherapist was blind to the randomization. Evaluation data were collected before and after treatment at weeks 4, 12, and 24. A 10 cm visual analog scale (VAS) was used to evaluate pain at rest and while working (0 indicated no pain and 10 the worst pain). A Jamar hand dynamometer (Lafayette Instrument, Lafayette, IN, USA) was used to evaluate handgrip strength. The Jamar hydraulic hand dynamometer has the ability to measure grip strength via an analogue display in two separate units (pounds and kilograms) up to 200 lb or 90 kg. Five different positions can be set for people with different hand sizes. Three measurements were performed while the elbow was at 90° flexion and the wrist in neutral position, and the average was recorded.

The SF36 Health Survey form was used to evaluate patients' quality of life. Koçyigˇit et al evaluated the validity and reliability of the Turkish version of this questionnaire.[@b22-jpr-11-1459] The SF36 is composed of 36 items, and the scale contains eight subscales: physical functioning, physical role functioning, bodily pain, general health, vitality, social functioning, emotional role functioning, and mental health. Scores in each subscale range from 0 to 100. Higher scores indicate better quality of life.[@b23-jpr-11-1459] The Turkish version of the Patient-Rated Tennis Elbow Evaluation (PRTEE-T) questionnaire was used to evaluate functioning of the affected arm during various daily life activities. The PRTEE-T questionnaire was validated by Altan et al[@b48-jpr-11-1459] in measuring changes in functional impairment. The PRTEE is composed of two subscales: pain (five questions); functional disability (ten questions), with functional disability composed of two subtitles -- specific activities (six questions) and usual activities (four questions) -- and 15 questions. In calculation, the average of the sum of specific activities and usual activities scales and the sum of pain scale are evaluated over 100. Low scores indicate that daily life activities are better. The questionnaire has considerably high reliability.[@b24-jpr-11-1459],[@b25-jpr-11-1459] We used Nirschl scores to assess pain in the affected arm during exercise. Patients were then instructed to mark the most appropriate option indicating the severity of pain during exercise on a Nirschl scale of 1--7 to evaluate pain in the affected arm during exercise. Low scores indicated lower intensity of pain during exercise in the affected arm.[@b26-jpr-11-1459] Three males and one female in the ESWT group and one male in the WES group failed to complete the treatment. These patients were excluded from the study.

Statistical analysis
--------------------

In the statistical evaluation of our data, SPSS 15.0 for Windows program was used. Quantitative variables are presented as mean ± SD and categorical variables as number and percentage. Data were tested for normal distribution. The independent *t*-test was used for paired comparisons of normally distributed variables of the ESWT and WES groups at 4, 12, and 24 weeks. Variables of the ESWT and WES groups without normal distribution at 4, 12, and 24 weeks were compared using the Mann--Whitney *U* test. In comparison to the variables of the ESWT and WES groups at 4, 12, and 24 weeks, analysis of variance was used in repeated measurements. The χ^2^-test was used to compare qualitative variables of the groups. Hypotheses were two-tailed, and *P*≤0.05 was considered statistically significant. While the power analysis of the number of subjects we set for randomization was 0.82 for each group (n=41), the power analysis of the number of subjects remaining after exclusion criteria was 0.76 for each group (n=36). In addition, the power analysis of the total number of all subjects taken into the study (n=67) was calculated to be 0.92.

Results
=======

Throughout the study period, no unfavorable condition was observed in the ESWT or WES groups. There was no statistically significant difference between the two groups in terms of demographic characteristics or evaluation parameters before treatment ([Table 1](#t1-jpr-11-1459){ref-type="table"}). In terms of the occupation of the patients in the ESWT group, two were unemployed, nine were workers, 12 were office employees, two were retired, and seven were housewives. In the WES group, there were three unemployed, 10 workers, 13 office employees, one retired, and eight housewives. There was no significant difference between the two groups according to the occupational distribution of the patients (*P*\>0.05). There was no statistically significant difference in terms of disease duration either (ESWT 27.69±7.92, WES 27.49±8.15; *P*\>0.05; [Table 1](#t1-jpr-11-1459){ref-type="table"}).

Mean VAS scores for pain at rest and pain while working before treatment in the ESWT group were 4.8±1.4 and 7.2±2.6, respectively, whereas mean VAS scores after treatment were 2.2±1.0 and 3.2±1.7 at 4 weeks (54.17% and 55.6% reduction in pain), 1.9±0.9 and 2.9±1.7 at 12 weeks (60.5% and 59.8% reduction in pain), and 2.4±1.1 and 3.7±1.8 at 24 weeks (50.0% and 48.7% reduction in pain). There were statistically significant increases in grip strength at 4, 12, and 24 weeks after treatment compared to pretreatment values (*P*\<0.001). There were significant increases in PRTEE-T and Nirschl scores, which evaluated function and pain in the affected arm in various daily life activities at 4, 12, and 24 weeks compared to pretreatment values (*P*\<0.001). In addition, there were considerably significant improvements in all subscales of the SF36 (general health, physical functioning, physical role functioning, emotional role functioning, social functioning, bodily pain, mental health, and vitality) at 4, 12, and 24 weeks compared to pretreatment values (*P*\<0.001; [Table 2](#t2-jpr-11-1459){ref-type="table"}).

Mean VAS scores for pain at rest and pain while working before treatment in the WES group were 4.7±1.5 and 7.3±2.5, respectively, whereas mean VAS scores after treatment were 2.1±1.1 and 3.3±1.9 at 4 weeks (55.4% and 54.8% reduction in pain), 1.9±1.2 and 3.1±1.8 at 12 weeks (59.6% and 57.6% reduction in pain), and 2.4±1.2 and 3.4±1.9 at 24 weeks (49.0% and 53.5% reduction in pain). There were statistically significant increases in grip strength at 4, 12, and 24 weeks after treatment compared to pretreatment values (*P*\<0.001). There were significant increases in PRTEE-T and Nirschl scores evaluating functioning and pain of the affected arm in various daily life activities at 4, 12, and 24 weeks compared to pretreatment values (*P*\<0.001). In addition, there were significant improvements in all subscales of the SF36 at 4, 12, and 24 weeks compared to pretreatment values (*P*\<0.001; [Table 3](#t3-jpr-11-1459){ref-type="table"}).

However, when results for WES patients in the ESWT and WES groups before treatment (at week 0) and after treatment (at weeks 4, 12, and 24) were compared, no statistically significant difference was found between the groups in terms of VAS scores for pain at rest, pain while working, grip strength, PRTEE-T and Nirschl scores evaluating functioning and pain of the affected arm in various daily life activities, or any subscale of the SF36 (*P*\>0.05; [Table 4](#t4-jpr-11-1459){ref-type="table"}).

Discussion
==========

Several studies have evaluated the efficacy of ESWT and WESs. However, there has been no study evaluating the efficacy of these two methods comparatively. In our study, we compared the efficacy of these methods. There was no statistically significant difference between demographic and clinical characteristics of patient groups after randomization. The homogeneous distribution of the groups may indicate that results obtained after treatment were highly independent of pretreatment values.

In a systematic review, it was reported that LE was observed equally in males and females, but more frequently in male tennis players than female tennis players.[@b27-jpr-11-1459] In addition, according to the literature, LE is observed in the dominant hand more frequently.[@b8-jpr-11-1459] In our study, numbers of female and male patients were similar to each other (ESWT male/female 15/17, WES 19/16). In addition, similarly to Dundar et al,[@b8-jpr-11-1459] we found that LE was seen in the dominant hand more frequently (ESWT 24/8, WES 27/8). In the majority of studies on LE, VAS has been used to evaluate pain, and it has been stated that a 1-point change in VAS score might be of clinical significance. In some studies, on the other hand, a 50% reduction in VAS score from baseline was considered significant.[@b28-jpr-11-1459],[@b29-jpr-11-1459] In our study, we obtained 2.4--2.9 points of change in VAS scores compared to baseline values and reduction \>50% in both ESWT and WES groups. Measuring grip strength is an objective method of evaluating treatment response and functional recovery.[@b30-jpr-11-1459] In our study, we used a hand dynamometer to evaluate grip strength. We noted significant improvement in both groups (ESWT, WES).

In many studies, the PRTEE scale was used to assess arm disability.[@b31-jpr-11-1459]--[@b33-jpr-11-1459] PRTEE was shown to be an appropriate test in evaluating LE. In our study, we used the PRTEE-T. We obtained statistically significant results in PRTEE scores at 4, 12, and 24 weeks compared to pretreatment values. Similarly, SF36 subscales have been used to evaluate quality of life in many studies. It has been emphasized that it is an important scale evaluating the quality of life.[@b34-jpr-11-1459]--[@b36-jpr-11-1459] We also used SF36 subscales in our study. We obtained improvements in both ESWT and WES groups compared to pretreatment values. We planned a four-session treatment with a similar design to that of Pettrone et al[@b37-jpr-11-1459] with 2,000 pulses per session. Although application interval varies, in our study we applied ESWT with 7-day intervals, because generally accepted opinion for sufficient level of effectiveness is applying sessions with 5- to 7-day intervals.[@b38-jpr-11-1459]

In the literature, there have been conflicting reports on the efficacy of ESWT in the treatment of LE. According to some publications, there is a reduction in pain and increase in functions and grip strength after ESWT application,[@b5-jpr-11-1459],[@b39-jpr-11-1459],[@b40-jpr-11-1459] while according to some other studies, strong evidence was provided that ESWT has little or no benefit for lateral elbow pain.[@b13-jpr-11-1459],[@b41-jpr-11-1459]--[@b43-jpr-11-1459] On the other hand, there have been studies advocating that ESWT is a treatment method yielding successful results, especially in persistent LE cases.[@b44-jpr-11-1459],[@b45-jpr-11-1459] The reason for these conflicting results might be differences in the number of pulses delivered, frequency, duration of application, treatment interval, and different devices used, depending on the different treatment protocols used. This is because when the literature is examined, it is seen that ESWT does not have a standard treatment protocol for LE, and different numbers of pulses, frequencies, duration of application, treatment intervals, and device applications are available.

There have been many studies comparing ESWT and different treatment methods in the treatment of LE. In a study in which ESWT and cryoultrasound were compared in a 1-year follow-up, Vulpiani et al obtained results in favor of ESWT at 6 months and at the end of 1 year in terms of VAS scores and patient satisfaction.[@b38-jpr-11-1459] Lee et al compared the efficacy of ESWT and corticosteroid injection in their study on patients with newly diagnosed LE and medial epicondylitis.[@b46-jpr-11-1459] They concluded that ESWT was as effective as injections after treatment and during the 8-week follow-up. Ozturan et al[@b15-jpr-11-1459] divided 60 patients with a complaint \>6 months into three treatment groups and compared the effectiveness of corticosteroid injection, autologous blood, injection, and ESWT. In their study, while evaluating patients with the Thomsen test, upper-extremity function scores and grip strength during a 52-week follow-up were measured and found that the corticosteroid group was superior to the other groups at 4 weeks in terms of VAS and grip strength, but this superiority did not continue in the subsequent follow-ups. It was reported at 52 weeks of follow-up period that the corticosteroid injection had a success rate of 50%, autologous blood injection had a success rate of 83%, and ESWT had a success rate of 89%. Radwan et al stated that ESWT could be an alternative noninvasive treatment method to surgery. They reported that complications of ESWT were minor, it was easy to administer and noninvasive, yielded successful results close to surgery, and had a significant advantage in terms of cost-effectiveness.[@b16-jpr-11-1459] However, no study was found in the literature comparing ESWT and splint application. In this sense, our study is an important work in this area.

When comparisons of ESWT with other physical therapy modalities were examined, ESWT was reported to be as effective as and even more effective than cryoultrasound, corticosteroid injection, autologous blood injection, massage, and laser applications, and that it could be an alternative to surgery. In our study, we also found that ESWT is as effective as WES.

Splinting is one of the conservative methods commonly used in the treatment of LE. The most commonly used orthoses are forearm-counterforce braces, resting hand--wrist splints, and WESs, which allow the muscle to rest in the acute phase and provide proprioceptive input in the chronic phase.[@b8-jpr-11-1459] Splints can make daily life activities easier, decrease pain, and increase grip strength, and they are affordable. However, there have been no definite conclusions reported on the effectiveness of orthoses in the treatment of LE, because of variability in control groups, outcome measures, type of splint used, duration of complaints, prognostic factors, and low number of patients.[@b47-jpr-11-1459] In a study conducted by Altan et al,[@b48-jpr-11-1459] a reduction in pain was detected with the use of an LE band and a wrist-resting splint, which held the wrist slightly dorsiflexed, in patients with LE \<3 months. However, there was no significant difference between the two splints in terms of effectiveness in the long term. Similarly to Altan et al, we also used a splint in our study, which held the wrist in extension (dorsiflexion). We achieved significant pain relief and improvement in grip strength and quality of life. In general terms, although there have been studies reporting that splinting in LE was effective in decreasing pain and improving grip strength,[@b8-jpr-11-1459],[@b47-jpr-11-1459]--[@b49-jpr-11-1459] in a retrospective cohort study conducted by Derebery et al,[@b50-jpr-11-1459] it was reported that patients with LE who were followed with splinting had higher revisit rates and longer treatment duration compared with patients who were treated without splinting. It was stated that early mobilization might be more effective than resting and immobilization provided by bandage might delay healing. In a systematic review of studies that compared splinting with conservative therapies, no difference was found between splinting, physiotherapy, or topical nonsteroidal anti-inflammatory drugs, whereas in one study corticosteroid injection was found to be superior in the early period.[@b47-jpr-11-1459] In our study, we found that WES was as effective as ESWT in decreasing pain, increasing grip strength, and improving quality of life.

Presently, there is no universally accepted and standardized LE-treatment program. For this reason, we examined the effectiveness of ESWT and WESs both in themselves and in comparison with each other. Both treatment methods were noninvasive, painless, and easy to apply. In conclusion, we found that ESWT and WES were considerably effective in decreasing pain, improving grip strength, increasing quality of life, and alleviating arm pain during daily life activities in the treatment of LE. It can be said that ESWT and WES are effective conservative treatment options in the treatment of LE. As both methods are comparable in terms of efficacy, when we evaluate ESWT and WES in terms of cost-effectiveness and efficacy, WES seems to be slightly more advantageous than ESWT, because WES is cheap, easy to apply, and does not cause complications. We recommend the use of WES in terms of cost-effectiveness and efficacy. Our study has some limitations. The SF36, PRTEE, and Nirschl questionnaires are patient-reported instruments, and the number of patients in the study was low.
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![Flowchart for participants randomized to receive ESWT or WES.\
**Abbreviations:** ESWT, extracorporeal shock-wave therapy; WES, wrist-extensor splint.](jpr-11-1459Fig1){#f1-jpr-11-1459}

###### 

Comparison of demographic characteristics between ESWT and WES groups

  Demographic features              ESWT (n=32), mean ± SD/n   WES (n=35), mean ± SD/n   *P*
  --------------------------------- -------------------------- ------------------------- -------
  Age, years                        38.84±6.77 (26/56)         37.94±6.45 (27/54)        0.809
  Sex, male/female                  15/17 (46.87%/53.13%)      19/16 (54.28%/45.72%)     0.544
  BMI, kg/m^2^                      27.21±1.38 (24.5/30.1)     26.34±2.29 (22.1/31.5)    0.398
  Dominant hand right/left          28/4 (87.5%/12.5%)         30/5 (85.71%/14.29%)      0.830
  Disease duration (days)           27.69±7.92 (15--44)        27.49±8.15 (14--44)       0.778
  Side of involvement, right/left   24/8 (75%/25%)             27/8 (77.14%/22.86%)      0.837
  Occupation                                                                             
   Unemployed                       2 (6.25%)                  3 (8.57%)                 0.436
   Working                          9 (28.12%)                 10 (28.57%)               0.886
   Officer                          12 (37.50%)                13 (37.14%)               0.812
   Retired                          2 (6.25%)                  1 (2.85%)                 0.312
   Housewife                        7 (21.87%)                 8 (22.85%)                0.737

**Abbreviations:** ESWT, extracorporeal shock-wave therapy; WES, wrist-extensor splint; BMI, body-mass index.

###### 

Results and statistical comparisons of pretreatment (week 0) and posttreatment (after 4, 12, and 24 weeks) parameters in ESWT group (n=32)

  Elbow pain and QOL        Baseline (week 0)   After 4 weeks   After 12 weeks   After 24 weeks   *P* (week 0--week 4)   *P* (week 0--week 12)   *P* (week 0--week 24)
  ------------------------- ------------------- --------------- ---------------- ---------------- ---------------------- ----------------------- -----------------------
  Pain at rest (VAS)        4.8±1.4             2.2±1.0         1.9±0.9          2.4±1.1          \<0.001                \<0.001                 \<0.001
  Pain under strain (VAS)   7.2±2.6             3.2±1.7         2.9±1.7          3.7±1.8          \<0.001                \<0.001                 \<0.001
  Grip strength (kg)        22.2±11.9           26.1±12.8       26.9±13.0        24.9±12.1        \<0.001                \<0.001                 \<0.001
  PRTEE-T                   60.5±22.3           41.5±18.2       39.3±18.1        47.5±21.3        \<0.001                \<0.001                 \<0.001
  Nirschl                   5.7±0.9             3.1±0.7         3.02±0.8         3.7±0.8          \<0.001                \<0.001                 \<0.001
  SF36                                                                                                                                           
   GH                       60.2±17.1           74.8±21.0       71.9±19.1        68.9±18.2        \<0.001                \<0.001                 \<0.001
   PF                       54.3±11.5           70.9±13.8       67.6±13.2        64.6±12.0        \<0.001                \<0.001                 \<0.001
   RLPR                     60.7±25.7           71.0±27.2       73.4±26.9        69.1±26.5        \<0.001                \<0.001                 \<0.001
   RLER                     59.3±19.7           68.7±22.1       71.8±23.0        66.6±21.1        \<0.001                \<0.001                 \<0.001
   SF                       59.7±16.6           70.1±23.1       72.5±23.3        68.1±18.2        \<0.001                \<0.001                 \<0.001
   BP                       54.7±13.4           66.6±16.4       67.0±16.7        62.1±15.9        \<0.001                \<0.001                 \<0.001
   MH                       55.0±18.1           65.0±22.1       64.5±21.9        61.3±20.2        \<0.001                \<0.001                 \<0.001
   V                        51.8±14.3           67.6±18.2       68.9±14.4        63.2±16.8        \<0.001                \<0.001                 \<0.001

**Abbreviations:** ESWT, extracorporeal shock-wave therapy; VAS, visual analog scale; PRTEE-T, Patient-Rated Tennis Elbow Evaluation -- Turkish; GH, general health; PF, physical functioning; RLPR, role limitation -- physical reasons; RLER, role limitation -- emotional reasons; SF, social function, BP, bodily pain; MH, mental health; V, vitality; QOL, quality of life.

###### 

Results and statistical comparisons of pretreatment (week 0) and posttreatment (after 4, 12 and 24 weeks) evaluation parameters in WES group (n=35)

  Elbow pain and QOL        Baseline (week 0)   After 4 weeks   After 12 weeks   After 24 weeks   *P* (week 0--week 4)   *P* (week 0--week 12)   *P* (week 0--week 24)
  ------------------------- ------------------- --------------- ---------------- ---------------- ---------------------- ----------------------- -----------------------
  Pain at rest (VAS)        4.7±1.5             2.1±1.1         1.9±1.2          2.4±1.2          \<0.001                \<0.001                 \<0.001
  Pain under strain (VAS)   7.3±2.5             3.3±1.9         3.1±1.8          3.4±1.9          \<0.001                \<0.001                 \<0.001
  Grip strength (kg)        22.1±9.2            26.1±11.1       26.5±11.7        24.9±10.3        \<0.001                \<0.001                 \<0.001
  PRTEE-T                   61.3±19.7           43.3±13.1       39.3±12.3        46.1±13.9        \<0.001                \<0.001                 \<0.001
  Nirschl                   5.8±1.3             3.1±0.8         3.1±0.9          3.5±1.0          \<0.001                \<0.001                 \<0.001
  SF36                                                                                                                                           
   GH                       61.5±19.5           76.4±26.4       74.6±25.9        71.5±23.3        \<0.001                \<0.001                 \<0.001
   PF                       53.3±13.6           69.2±18.1       69.4±17.6        64.5±16.3        \<0.001                \<0.001                 \<0.001
   RLPR                     58.6±22.6           71.4±27.2       72.8±26.9        67.8±25.7        \<0.001                \<0.001                 \<0.001
   RLER                     60.9±22.4           69.4±24.4       72.3±24.9        65.6±23.1        \<0.001                \<0.001                 \<0.001
   SF                       58.9±27.7           70.7±34.1       73.9±33.7        66.1±30.8        \<0.001                \<0.001                 \<0.001
   BP                       53.7±14.2           67.3±19.6       67.7±20.1        60.8±17.5        \<0.001                \<0.001                 \<0.001
   MH                       53.6±14.9           68.2±22.1       67.1±21.3        58.7±17.4        \<0.001                \<0.001                 \<0.001

**Abbreviations:** WES, wrist-extensor splint; VAS, visual analog scale; PRTEE-T, Patient-Rated Tennis Elbow Evaluation -- Turkish; GH, general health; PF, physical functioning; RLPR, role limitation -- physical reasons; RLER, role limitation -- emotional reasons; SF, social function, BP, bodily pain; MH, mental health; QOL, quality of life.

###### 

Comparison of ESWT and WES groups on basis of pretreatment (0 week) and posttreatment (after 4, 12, and 24 weeks)

  Elbow pain and QOL        Week 0, ESWT (pretreatment)   Week 0, WES (pretreatment)   *P*     Week 4, ESWT   Week 4, WES   *P*     Week 12, ESWT   Week 12, WES   *P*     Week 24, ESWT   Week 24, WES   *P*
  ------------------------- ----------------------------- ---------------------------- ------- -------------- ------------- ------- --------------- -------------- ------- --------------- -------------- -------
  Pain at rest (VAS)        4.84±1.4                      4.74±1.5                     0.790   2.2±1.0        2.1±1.1       0.833   1.9±0.9         1.9±1.2        0.812   2.3±1.1         2.4±1.2        0.707
  Pain under strain (VAS)   7.21±2.6                      7.31±2.5                     0.496   3.2±1.7        3.3±1.9       0.638   2.9±1.7         3.1±1.8        0.260   3.7±1.8         3.4±1.9        0.399
  Grip strength (kg)        22.25±11.92                   22.11±9.22                   0.553   26.2±12.8      26.1±11.1     0.963   26.9±13.0       26.5±11.7      0.756   24.3±12.1       24.9±10.3      0.669
  PRTEE-T                   60.50±22.3                    61.31±19.7                   0.855   42.5±18.2      43.3±13.1     0.919   40.3±18.1       39.3±12.3      0.484   47.5±21.3       46.1±13.9      0.409
  Nirschl                   5.75±0.96                     5.8±1.3                      0.641   3.1±0.7        3.1±0.8       0.907   3.02±0.8        3.1±0.9        0.911   3.7±0.8         3.5±1.0        0.905
  SF36                                                                                                                                                                                                    
  GH                        60.28±17.1                    61.54±19.5                   0.443   74.8±21.0      76.4±26.4     0.178   72.9±19.1       74.6±25.9      0.343   68.9±18.2       71.5±23.3      0.187
  PF                        54.37±11.5                    53.28±13.6                   0.913   70.9±13.8      69.2±18.1     0.853   67.6±13.2       69.4±17.6      0.733   65.9±12.0       65.5±16.3      0.775
  RLPR                      60.75±25.7                    58.57±22.6                   0.816   71.0±27.2      71.4±27.2     0.971   73.4±26.9       72.8±26.9      0.869   69.1±26.5       67.8±25.7      0.883
  RLER                      59.32±19.7                    60.95±22.4                   0.920   68.7±22.1      69.4±24.4     0.866   71.8±23.0       72.3±24.9      0.920   66.6±21.1       65.6±23.1      0.853
  SF                        59.76±16.6                    58.92±27.7                   0.824   70.1±23.1      70.7±34.1     0.793   72.5±23.3       73.9±33.7      0.511   68.1±18.2       66.1±30.8      0.631
  BP                        54.75±13.4                    53.71±14.2                   0.643   66.6±16.4      67.3±19.6     0.464   67.0±16.7       67.7±20.1      0.842   62.1±15.9       60.8±17.5      0.323
  MH                        55.06±18.1                    53.60±14.9                   0.239   65.0±22.1      68.2±22.1     0.173   64.5±21.9       67.1±21.3      0.085   61.3±20.2       58.7±17.4      0.572
  V                         51.87±14.3                    48.28±9.6                    0.099   67.6±18.2      69.8±16.2     0.201   69.9±14.4       71.1±17.0      0.099   63.2±16.8       61.5±13.1      0.455

**Abbreviations:** ESWT, extracorporeal shock-wave therapy; WES, wrist-extensor splint; VAS, visual analog scale; PRTEE-T, Patient-Rated Tennis Elbow Evaluation -- Turkish; GH, general health; PF, physical functioning; RLPR, role limitation -- physical reasons; RLER, role limitation -- emotional reasons; SF, social function, BP, bodily pain; MH, mental health; V, vitality; QOL, quality of life.
